Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes.
Haematologica
; 92(8): 1119-22, 2007 Aug.
Article
em En
| MEDLINE
| ID: mdl-17650442
ABSTRACT
Valproic acid (VPA), an inhibitor of histone deacetylases, inhibits the growth of leukemia cells and induces their differentiation in vitro. In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML. Eight patients had to discontinue treatment before week 16 due to toxicity. According to international working group criteria, three patients (16%) responded to treatment. No correlation between VPA serum level, histone acetylation or clinical response was observed.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Síndromes Mielodisplásicas
/
Calcitriol
/
Isotretinoína
/
Ácido Valproico
Tipo de estudo:
Clinical_trials
/
Etiology_studies
Limite:
Aged
/
Aged80
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article